Abstract: Methods are disclosed for treating inflammatory disease states in a mammalian patient (e.g., human) by applying noninvasive focused ultrasound stimulation to the celiac-superior mesenteric ganglion complex of the patient.

Abstract: This disclosure relates to a rapid, colorimetric assay that detects choline acetyl transferase (hereafter “ChAT”) in biological samples. The inventive colorimetric assay can be used to measure and monitor extracellular levels of ChAT in a subject, such as a human or non-human animal, thereby improving the treatment of disease states where ChAT has been identified as a biomarker.

Abstract: Compositions and methods are provided comprising choline acetyltransferase (ChAT) and PEGylated ChAT for treating hypertension.

Abstract: Disclosed are apparatuses and methods for reducing or limiting bleeding (e.g., blood loss and/or bleeding time) in an animal by trigeminal stimulation. The apparatuses and methods may activate one or more branches of the trigeminal nerve. This activation may be invasive or non-invasive.

Abstract: The present invention provides methods for modulating antigen-specific antibody responses by administering to a mammal a compound that selectively either activates or inhibits a specific subset of sensory neurons that express TRPV1.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: The present disclosure relates to systems, methods and devices to monitor, diagnose and/or treat diseases or disorders comprising a calibration phase and a real-time diagnostic, treatment or monitoring phase, the calibration phase correlating a plurality of nerve activity measurements from a chronically implanted electrode in a subject with a plurality of concurrent measurements of levels of cytokines and/or glucose in the blood to obtain a functional relationship between blood cytokine and/or glucose levels and vagus nerve activity, and the diagnostic, treatment or monitoring phase analyzing the subject's real-time vagus nerve activity in accordance with the previously obtained functional relationship to initiate a treatment method.

Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.

Abstract: Methods for electrical modulation of inflammation or serum TNF levels in a subject.

Abstract: Disclosed are apparatuses and methods for reducing or limiting bleeding (e.g., blood loss and/or bleeding time) in an animal by trigeminal stimulation. The apparatuses and methods may activate one or more branches of the trigeminal nerve. This activation may be invasive or non-invasive.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: Methods of treating HMGB1-mediated inflammation by administering a therapeutically effective amount of an MD2-antagonist to a subject in need thereof are described. The novel MD2 antagonist tetrapeptide P5779 is also described.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising stimulating a nerve of the subject with a corrective stimulus pattern derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: Provided are anti-tetranectin domain-specific antibodies and fragments thereof, as well as methods of use employing such antibodies and/or fragments.

Abstract: A method and an apparatus for treating a patient suffering from, or at risk for, a condition mediated by the inflammatory cytokine cascade, by electrically stimulating vagus nerve activity in an amount sufficient to inhibit the inflammatory cytokine cascade.

Abstract: Provided are CD4+ T-cell-based compositions and methods for treating hypertension.

Abstract: Methods are disclosed for treating a subject having a disease or disorder comprising providing the subject with an acoustic energy stimulus derived from a disease-specific, condition-specific, endogenous mediator-specific or pharmacologic agent-specific neurogram in an amount and manner effective to treat the disease or disorder.

Abstract: Compositions and methods are provided comprising choline acetyltransferase (ChAT) and PEGylated ChAT for treating hypertension.

Abstract: Methods are disclosed for treating a subject with metabolic syndrome, fatty liver disease, insulin resistance, inflammation or elevated body weight using hepatic ultrasound.

Abstract: Described herein are methods for treating a subject suffering from or at risk for a condition mediated by an inflammatory cytokine cascade, by electrically or mechanically stimulating vagus nerve activity in an amount sufficient to inhibit the inflammatory cytokine cascade.